Rose Hip for Health & Longevity - Quick Reference Sheet

Rose Hip for Health & Longevity

Created on 10/21/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 Astra – Audit

Rose hip is a plant-derived supplement used for joint symptom relief. Benefits remain inconsistent and preparation-dependent; no longer human life has been demonstrated. Possible symptom improvement may support activity, but digestive discomfort, allergy, medication-absorption changes, misleading laboratory results, and uncertain long-term safety matter. A clearly identified product and a defined, observable outcome are more meaningful than broad antioxidant claims. (Full Review)

Protocol

Joint-trial approach:
2.5 g orally twice daily
Standardized seed-and-husk powder; 5 g/day for four months. Not proof all powders work.
Extract experiment:
100 mg/day for 12 weeks
Standardized extract, at least 0.1% tiliroside; no universal extract-to-powder ratio.
Timing and persistence:
Divided powder doses with meals
Reference practice; no morning-versus-evening advantage established.
Time to effect
Symptoms on standing in adults with diabetes
4 weeks
Short trial assessment; not general falls prevention.
Positive urine cultures after cesarean delivery
Days 7–10 and 20
Postoperative assessment windows; symptomatic bladder infection was not significantly reduced.
Joint pain and physical function
3–4 months
Assessment window, not promised onset or sustained benefit.

Benefits

Contraindications
  • Known rose hip allergy
  • Pregnancy or breastfeeding (precautionary avoidance of concentrated supplementation)
Key Interactions
  • Paracetamol/acetaminophen
  • Digoxin
  • Blood-pressure medications (amlodipine) (theoretical)
  • Glucose-lowering medications (insulin) (theoretical)
  • Anticoagulants (warfarin) (theoretical)
  • Other oral medicines (theoretical)
  • Supplements (theoretical)
  • Procedures

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal symptoms; allergy; eye inflammation after raw-fruit contact; misleading digoxin test results; liver injury from multi-herb products
  • Speculative: Problems from high vitamin C exposure; uterine stimulation during pregnancy

Monitoring

Marker Target Why
Resting blood pressure No established target; track change from baseline Expected-effect and symptomatic-low-pressure check
Low-density lipoprotein cholesterol No established target; track change from baseline Expected-effect marker

Cadence: Baseline; tolerance weekly; pressure at 2–6 weeks; cholesterol at 6–12 weeks; joint symptoms and activity at baseline, 6 and 12 weeks. Pragmatic intervals, not a validated safety schedule.

Qualitative Assessment

  • Joint experience: Task-related pain, stiffness, walking tolerance, rescue-medication use.
  • Tolerance: Stool changes, nausea, rash, dizziness.
  • Sleep and energy: Secondary observations remain difficult to attribute.